Citizens analyst Jonathan Wolleben lowered the price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV) to $28.00 (from $29.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE